Salman S Allana1,2, Furqan A Rajput3, Jason W Smith4, Lucian Lozonschi5, Jinn-Ing Liou6, Maryl Johnson1, Takushi Kohmoto7, Ravi Dhingra8. 1. Department of Medicine, Cardiovascular Division, School of Medicine & Public Health, University of Wisconsin-Madison, 600 Highland Avenue, E5/582; MC 5710, Madison, WI, 53792, USA. 2. Cardiovascular Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. 3. Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA. 4. Cardiothoracic Surgery, University of Wisconsin-Madison, Madison, WI, USA. 5. Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC, USA. 6. Department of Epidemiology and Biostatistics, University of Wisconsin-Madison, Madison, WI, USA. 7. Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI, USA. 8. Department of Medicine, Cardiovascular Division, School of Medicine & Public Health, University of Wisconsin-Madison, 600 Highland Avenue, E5/582; MC 5710, Madison, WI, 53792, USA. rdhingra@medicine.wisc.edu.
Abstract
PURPOSE: It remains unclear if use of amiodarone pre-cardiac transplantation impacts early post-transplant survival. METHODS: We selected all patients undergoing heart transplant from 2004 to 2006 with available information using the United Network for Organ Sharing database (n = 4057). Multivariable Cox models compared the risk of death within 30 days post-transplant in patients who were taking amiodarone at the time of transplant listing (n = 1227) to those who were not (n = 2830). RESULTS: Mean age was 52 (± 12) years, and 23% were women. Patients who died within 30 days (n = 168) were older; had higher panel reactive antibody levels, higher bilirubin levels, and higher prevalence of prior cardiac surgery; were often at status 1B; and had higher use of amiodarone at listing compared to those who survived (5.3% versus 3.6%; p = 0.02). Cause of death was unknown in 49% and was reported as graft failure in 43% of cases. In multivariable Cox models, patients on amiodarone at the time of listing had 1.56-fold higher risk of post-transplant death within 30 days (95% confidence intervals 1.08-2.27) compared to patients who were not on amiodarone at listing (C-statistic 0.70). CONCLUSION: In conclusion, patients who reported taking amiodarone at the time of listing for transplant had a higher risk of death within 30 days post-transplant.
PURPOSE: It remains unclear if use of amiodarone pre-cardiac transplantation impacts early post-transplant survival. METHODS: We selected all patients undergoing heart transplant from 2004 to 2006 with available information using the United Network for Organ Sharing database (n = 4057). Multivariable Cox models compared the risk of death within 30 days post-transplant in patients who were taking amiodarone at the time of transplant listing (n = 1227) to those who were not (n = 2830). RESULTS: Mean age was 52 (± 12) years, and 23% were women. Patients who died within 30 days (n = 168) were older; had higher panel reactive antibody levels, higher bilirubin levels, and higher prevalence of prior cardiac surgery; were often at status 1B; and had higher use of amiodarone at listing compared to those who survived (5.3% versus 3.6%; p = 0.02). Cause of death was unknown in 49% and was reported as graft failure in 43% of cases. In multivariable Cox models, patients on amiodarone at the time of listing had 1.56-fold higher risk of post-transplant death within 30 days (95% confidence intervals 1.08-2.27) compared to patients who were not on amiodarone at listing (C-statistic 0.70). CONCLUSION: In conclusion, patients who reported taking amiodarone at the time of listing for transplant had a higher risk of death within 30 days post-transplant.
Authors: Lars H Lund; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Anne I Dipchand; Samuel Goldfarb; Bronwyn J Levvey; Bruno Meiser; Joseph W Rossano; Roger D Yusen; Josef Stehlik Journal: J Heart Lung Transplant Date: 2015-08-28 Impact factor: 10.247
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff Journal: Circulation Date: 2013-06-05 Impact factor: 29.690
Authors: Lars H Lund; Leah B Edwards; Anna Y Kucheryavaya; Anne I Dipchand; Christian Benden; Jason D Christie; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Roger D Yusen; Josef Stehlik Journal: J Heart Lung Transplant Date: 2013-10 Impact factor: 10.247
Authors: Lars H Lund; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Jason D Christie; Anne I Dipchand; Fabienne Dobbels; Samuel B Goldfarb; Bronwyn J Levvey; Bruno Meiser; Roger D Yusen; Josef Stehlik Journal: J Heart Lung Transplant Date: 2014-08-14 Impact factor: 10.247
Authors: Mandeep R Mehra; John A Jarcho; Wida Cherikh; Muthiah Vaduganathan; Rebecca R Lehman; Jacqueline Smits; Josef Stehlik Journal: N Engl J Med Date: 2018-05-17 Impact factor: 91.245
Authors: Kiran K Khush; Wida S Cherikh; Daniel C Chambers; Michael O Harhay; Don Hayes; Eileen Hsich; Bruno Meiser; Luciano Potena; Amanda Robinson; Joseph W Rossano; Aparna Sadavarte; Tajinder P Singh; Andreas Zuckermann; Josef Stehlik Journal: J Heart Lung Transplant Date: 2019-08-10 Impact factor: 10.247
Authors: Christine M Durand; Mary G Bowring; Alvin G Thomas; Lauren M Kucirka; Allan B Massie; Andrew Cameron; Niraj M Desai; Mark Sulkowski; Dorry L Segev Journal: Ann Intern Med Date: 2018-04-17 Impact factor: 25.391